Shilpa Gupta, Professor, Staff, Hematology and Oncology at Cleveland Clinic, shared on LinkedIn:
“Thanks Thomas Powles, Brian Rini for having me on the The Uromigos podcast to discuss Tom’s famous UTUC poll– 400 votes, 4 nearly equally split options!
Not just controversy but an evidence gap!
- Adjuvant platinum – POUT showed benefit but driven by cisplatin, carboplatin benefit is less.
- Adjuvant IO: no benefit, underpowered UTUC subgroups in adjuvant trials.
- Surveillance with ctDNA: Positivity may herald distant relapse.
- EV-P: Extrapolation despite no UTUC in peri-operative trials
We need a dedicated adjuvant IO UTUC trial with an ADC/ADC-IO.
You can also read:
What Comes Next? Treatment Sequencing in Advanced Urothelial Carcinoma
